MTAP and digestive system neoplasm: These results are in line with previous reports on the prevalence of MTAP alterations in GI cancers, confirming the enrichment of such molecular feature in upper-GI malignancies.19, 23 In addition, our findings bring new knowledge regarding the very low prevalence of MTAP loss in lower-GI tumours (<1% in CRC).